

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252917 A2

- (51) International Patent Classification:
G01N 33/53 (2006.01)
- (21) International Application Number:
PCT/US2021/037039
- (22) International Filing Date:
11 June 2021 (11.06.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/037,968 11 June 2020 (11.06.2020) US
110102871 26 January 2021 (26.01.2021) TW
63/192,242 24 May 2021 (24.05.2021) US
17/345,495 11 June 2021 (11.06.2021) US
- (71) Applicant: **PROVENTION BIO, INC.** [US/US]; 55
Broad Street, 2nd Floor, Red Bank, New Jersey 07701 (US).
- (72) Inventors: **LEON, Francisco**; 8501 River Rock Terrace,
Bethesda, Maryland 20817 (US). **HEROLD, Kevan C.**; 12
Pine Point Road, Norwalk, Connecticut 06853 (US).
- (74) Agent: **DYKEMAN, David J.** et al.; Greenberg Traurig,
LLP, One International Place, Suite 2000, Boston, Massa-
chusetts 02110 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,

(54) Title: METHODS AND COMPOSITIONS FOR PREVENTING TYPE 1 DIABETES




Figure 1A

(57) Abstract: Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T cells, which is indicative of successful prevention or delay of the onset of clinical T1D.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*